QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of Conventional vs IMRT

Not Recruiting

Trial ID: NCT00568425

Age - 30 Years-70 Years Condition - Anal Cancer Gender - All Accepting Healthy Volunteers - No

Purpose

The purpose of this study is show that intensity-modulated radiotherapy (IMRT), as compared with conventional radiotherapy, improves the precision of tumor targeting and reduces the acute and late effects of radiation toxicity when used to treat anal cancer. Results from this work will provide a basis for incorporating the use of IMRT to treat anal cancer in future treatment protocols.

Official Title

Quality of Life and Functional Outcomes After Combined Modality Therapy for Anal Cancer: A Comparison of Conventional Versus Intensity-Modulated Radiation Therapy (ANAL0002)

Stanford Investigator(s)

Andrew A. Shelton, MD, FACS, FACRS
Andrew A. Shelton, MD, FACS, FACRS

Clinical Professor, Surgery - General Surgery

Eligibility


Inclusion Criteria:Histologically confirmed diagnosis of squamous cell carcinoma of the
anus. Must be able to provide informed consent. Exclusion Criteria:History of new
malignancy since the time of treatment for anal cancer. Non-English speaking.

View More
View Less

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Moe Jalali
6507244023

New Trial Alerts

©2024 Stanford Medicine